Skandinaviska Enskilda Banken AB publ Boosts Holdings in Amedisys, Inc. (NASDAQ:AMED)

Skandinaviska Enskilda Banken AB publ increased its holdings in Amedisys, Inc. (NASDAQ:AMED) by 43.7% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,286 shares of the health services provider’s stock after purchasing an additional 8,000 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.08% of Amedisys worth $2,414,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Banque Cantonale Vaudoise purchased a new position in Amedisys in the 1st quarter worth approximately $60,000. Innealta Capital LLC bought a new position in shares of Amedisys in the second quarter worth approximately $64,000. Covestor Ltd increased its stake in shares of Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after buying an additional 447 shares during the period. Signaturefd LLC raised its holdings in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after buying an additional 530 shares during the last quarter. Finally, GAM Holding AG purchased a new stake in Amedisys during the 2nd quarter valued at $275,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Trading Down 0.4 %

NASDAQ:AMED opened at $96.87 on Tuesday. The company has a 50-day moving average price of $97.67 and a 200-day moving average price of $94.87. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of -151.36, a P/E/G ratio of 1.89 and a beta of 0.78. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. Amedisys, Inc. has a 12 month low of $89.55 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, topping the consensus estimate of $1.22 by $0.10. The business had revenue of $591.19 million during the quarter, compared to analyst estimates of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. Equities analysts predict that Amedisys, Inc. will post 4.66 EPS for the current year.

Analyst Upgrades and Downgrades

AMED has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective on the stock. in a research report on Monday, July 29th. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $100.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.